- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2003.
-
- Dec.03.2003
- Phase I Clinical Study with New HIV Drug (Oral CCR5 Antagonist) Completed in the US(13 KB)
-
- Nov.19.2003
- Ono and Dong-A Signed a License Agreement on Elaspol® 100 for Injection for Acute Lung Injury(38 KB)
-
- Sep.03.2003
- Construction of Ono's New Corporate Headquarters Building Completed(10 KB)
-
- Jul.15.2003
- Clinical Study with New HIV Drug (Oral CCR5 Antagonist)Commenced in the US(39 KB)
-
- May.27.2003
- Announcement of Termination of Exclusive License Agreement on Sivelestat (Elaspol® 100 for Injection) with Eli Lilly and Company(15 KB)
-
- May.16.2003
- Ono Pharmaceutical Announces Dissolution of a Subsidiary(10 KB)
-
- May.16.2003
- Notice regarding Repurchase of Ono Pharmaceutical's Own Shares(Under Article 210 of Japanese Commercial Code)(14 KB)
-
- May.16.2003
- Notice of Change in Number of Shares in One Trading Unit(10 KB)
-
- Apr.04.2003
- Loss from Revaluation of Securities for the Fiscal Year Ended March 31, 2003(17 KB)
-
- Feb.19.2003
- Announcement of Discontinuation of ONO-5816 Clinical Study for Diabetes(11 KB)
-
- Jan.21.2003
- Ono Announces Completion of Its Tsukuba Research Institute(15 KB)
-
- Jan.16.2003
- Ono and GlaxoSmithKline Signed a Worldwide Agreement on Development and Commercialisation of a New HIV Drug(10 KB)